Inhalation Sciences Sweden AB – today

The Company is engineering a drug development process to enable our clients to realise their drug development program from discovery through to proof-of-concept and early human studies using for instance, microdosing.

The technology platform enables short inhalation exposures with highly concentrated aerosols of respirable particles in a manner that mimics clinical exposures and consumes only small amounts of test substance. The objective is to be able to predict and validate the deposition, absorption, metabolism, and mechanism of action following inhalation of a drug in the human lung.

Our mission is to accelerate your drug discovery timelines and to reduce late stage attrition rates with our fast and reliable cutting-edge testing technologies when developing pharmaceuticals intended for inhalation administration.

The company has future plans to enter the areas of drug delivery, clinical diagnosis and environmental medicine.